Immunohistochemical staining of Catenin, beta  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Catenin, beta [Polyclonal] Antibody (cGMP).

$ 135.00$ 805.00
Please Select Product Options Below To View The Catalog Number.

Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Rabbit Undetermined

Product NumberDescriptionPrice
QIVD85-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD85-0.5ml Size: 0.5 ml, Format: Concentrate $ 475.00
QIVD85-1ml Size: 1 ml, Format: Concentrate $ 805.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:


Bioactivity (test results eg. IU/ml):

SKU: QIVD85-0.1ml
Catenin, beta General Information
Alternate Names
Molecular Weight
85.5 kDa
Chromosomal Location
p22.1 [chr: 3] [chr_start: 41194741] [chr_end: 41260096] [strand: 1]
Curated Database and Bioinformatic Data
Gene SymbolCTNNB1
Entrez Gene ID1499
RefSeq Protein Accession(s)NP_001895; NP_001091679; XP_005264943; NP_001091680; XP_016861227
RefSeq mRNA Accession(s)XM_006712983; XM_024453357; NM_001904; XM_017005738; XM_024453359; XM_024453360; NM_001098209; XM_024453358; NM_001330729; XM_024453356; NM_001098210; XM_006712985
RefSeq Genomic Accession(s)NG_013302; NC_000003
UniProt ID(s)P35222
PharmGKB ID(s)PA27013
KEGG Gene ID(s)hsa:1499
Associated Diseases (KEGG IDs)Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:9065402}. The gene represented in this entry may be involved in disease pathogenesis.; Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.; Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, ECO:0000269|PubMed:12027456}. The gene represented in this entry is involved in disease pathogenesis.; Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456}. The gene represented in this entry may be involved in disease pathogenesis.; Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:10391090}. Disease susceptibility is associated with variations affecting the gene represented in this entry.; A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.; Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:11464291}. The gene represented in this entry may be involved in disease pathogenesis.; Neurodevelopmental disorder with spastic diplegia and visual defects (NEDSDV) [MIM:615075]: An autosomal dominant disorder characterized by global developmental delay, severe intellectual disability with absent or very limited speech, microcephaly, spasticity, and visual abnormalities. {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:25326669, ECO:0000269|PubMed:28514307}. The disease is caused by mutations affecting the gene represented in this entry.; Vitreoretinopathy, exudative 7 (EVR7) [MIM:617572]: A form of exudative vitreoretinopathy, a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. {ECO:0000269|PubMed:28575650}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of Catenin, beta .
This antibody reacts with a 92 kDa protein, known as beta-catenin. The catenins (alpha, beta and γ) are ubiquitously expressed cytoplasmic proteins, which are associated with E-cadherin. beta-catenin can also bind to APC. Cadherin/catenin complexes are linked to the cytoskeleton via a direct association between alpha-actinin and alpha-catenin.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:100-1:200
Pretreatment Citrate Buffer pH 6.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Polyclonal
Anti-Catenin, beta Antibody Clone: Polyclonal
Host and Isotype: Rabbit Undetermined
Recommended Positive Control Sample: Breast carcinoma, Large intestine
Cellular Localization of Antibody Polyclonal Staining: Cytoplasmic, cell membrane
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: A synthetic peptide derived from the C-terminus of human beta-catenin protein.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Catenin, beta Information for Pathologists


Protein encoded by CTNNB1 gene, coordinates cell-cell adhesion and gene transcription (Wikipedia: Beta Catenin [Accessed 18 December 2018]). Pathophysiology Part of Wnt signalling pathway, highly conserved pathway with critical role in embryologic development (Dev Cell 2009;17:9), carcinogenesis and epithelial-to-mesenchymal transition. Upon Wnt activation, ? catenin is translocated from membrane (where it interacts with E-cadherin) to cytoplasm and nucleus, where it interacts with transcriptional activators. Clinical features

Notable Clinical Features:

Mutations and overexpression of ? catenin are associated with various carcinomas. Colon: plays a critical role in tumorigenesis (mutations in APC or ? catenin present in 90% of colon cancers). Thyroid: pathway important for anaplastic and possibly papillary thyroid carciomas (Front Endocrinol (Lausanne) 2012;3:31). Uterus: endometrioid endometrial carcinoma is associated with ? catenin mutations. Diagrams / tables

Common Uses By Pathologists:

Interpretation: nuclear staining is significant in fibroblasts; nuclear or cytoplasmic staining is significant in epithelial cells. Classify hepatocellular adenoma subtypes and distinguish from focal nodular hyperplasia (Am J Surg Pathol 2012;36:1691, Int J Hepatol 2013;2013:268625, Hum Pathol 2013;44:750). Positive / mutated in fibromatosis (Mod Pathol 2012;25:1551). Distinguish mesenteric fibromatosis (positive with nuclear staining due to mutations in APC / ? catenin pathway causing nuclear accumulation) from GIST tumors (negative) and sclerosing mesenteritis (negative, Am J Surg Pathol 2002;26:1296). Distinguish fibromatosis (diffuse or rarely focal nuclear staining for deep tumors) from low grade fibromyxoid sarcoma and other myofibroblastic, or fibroblastic tumors / sarcomas (negative for nuclear staining, Am J Surg Pathol 2005;29:653).

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Catenin, beta [Polyclonal] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title




  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Chat: See lower right corner. | | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Catenin, beta [Polyclonal] Antibody (cGMP).